FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
|Videos|November 30, 2020
Studying COVID-19 Long-Haulers
Author(s)John Parkinson
A team at Columbia University's Mailman School of Public Health is looking at the long term of effects in some patients who are suffering from this phenomenon.
Advertisement
Even before Mady Hornig’s experience with COVID-19 and her being a long-hauler, her team at Columbia University's Mailman School of Public Health was planning to study the long-term effects SARS-COV-2 on people with it.
Hornig, MA, MD, is an associate professor of epidemiology at Columbia University's Mailman School of Public Health.
“We had planned to do these studies well before I had any evidence of the illness,” Hornig said. “The long-hauler situation was one we anticipated might occur because of knowledge of other post-viral syndromes.”
Hornig has had a number of what would typically be unrelated symptoms including fever to COVID toes to hypertension. While she has maintained a battle with an overwhelming fatigue she has been gradually feeling better.
One of the interesting aspects the research is looking at is the connection of chronic fatigue syndrome symptoms and the overlap with the long-hauler phenomenon. Hornig notes that 10%-to 12% of those who suffer infectious mononucleosis get diagnosed with chronic fatigue syndrome.
In the second segment of an interview with Contagion®, Hornig offers insights into the specifics of their studies including addressing who is more at risk, inequities in care, and looking for potential solutions for precision medicine.
Advertisement
Related to this article
The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.
The antiviral did not produce greater symptom improvement than placebo in patients with the condition in the RECOVER-VITAL trial.
The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Star Meat Delivery is recalling approximately 167,639 pounds of raw pork, beef, and goat products produced without federal inspection.
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
Outcomes from treating orthopedic infection with debridement and implanted antibiotic were similar whether followed by short or standard duration of systemic antibiotic.
Advertisement
Advertisement
Trending on Contagion Live
1
US Company Recalls Thousands of Pounds of Uninspected Meat
2
Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions
3
Measles Update: September 25, 2026
4
How The Food Safety Surveillance Infrastructure Works in the US
5